ARCHIVES

Phase III Nexavar Trial Fails Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 8 | August 29, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995

In Brief: Clark, Hutchinson Gain New Honors; Nominations Open For Bristol-Myers Award; NIH Appointments

July 1, 1983

Clinton Budget Proposes Increase For AIDS, tuberculosis, In FY94

April 23, 1993

Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable

April 26, 2013

BioSeek Awarded NIH SBIR For Compound Validation.

July 4, 2003

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007